Minimization cost analysis of hospitalization of 40 patients affected by hemopoietic malignancies that underwent autologous bone marrow transplantation has been performed. Clinical records of 27 patients treated with Filgrastim have been compared with records of 13 patients not treated. The retrospective comparative analysis included days of hospitalization, antibiotic therapy, nursing time, transfusion episodes, microbiological cultures required. Overall average hospitalization cost since transplantation for treated patients was £65,537,774 versus £69,479,878 (p<0.004). Average hospitalization time since transplantation for treated patients was 29.3 days versus 32.7 for not treated. Thus, hospitalization after transplantation was 3.4 days (HR 5.3; 95% C.I. 2.0 to 13.9) shorter for treated, accounting for a 10.4% saving in hospitalization time. Treated patients had average 5.6 days less in sterile room (HR 5.0; 95% C.I. 2.0 to 12.4). Every treated patient hospitalization raised savings for at least £3.942.104, taking into account the average savings in hospitalization days after transplantation. Moreover, Filgrastim use lead to overall and "sterile" nursing timesavings of 6.5% and 16.8%, results in accordance with shorter hospitalization. Our results are similar to those reported by other studies. Suitable use of Filgrastim, reducing hospitalization length and disease course, appears to be a valid way to improve health-care efficiency.